美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · KROS近 30 天 4 則 · 第 1 / 1 頁
- Keros Therapeutics Announces $5 Million Share Repurchase Authorization
- Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
- KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
- Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
- Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
- KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
- Keros Therapeutics Reports Second Quarter 2026 Financial Results
- Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
- Keros Therapeutics Appoints Anne Prener to its Board of Directors
- Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
- KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
- Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
- Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
- Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
- Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
- Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
- Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
- Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。